Wallace Bourgeois

5PUBLICATIONS
60CO-AUTHORS
Molecular targetsGene and molecular therapyHaematological tumoursObstetrics and gynaecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 09, 2026
Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues.

|Jun 19, 2025
Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia.

Shellaina J V Gordon, Florian Perner, Laura MacPherson

|Mar 27, 2024
Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia.

Wallace Bourgeois, Edward Yang, Roberto Chiarle

|Dec 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.

Wallace Bourgeois, Jevon A Cutler, Brandon J Aubrey

|Jul 21, 2021
Juvenile Granulosa Cell Tumor as the Presenting Feature of McCune-Albright Syndrome.

Brynn E Marks, Ronan Sugrue, Wallace Bourgeois

Pageof 1

Frequent Collaborators

2 joint publications

Daniela V Wenge

2 joint publications

Scott A Armstrong

2 joint publications

Katherine A Donovan

1 joint publications

Brynn E Marks